BioCurex Licenses RECAF Technology to Inverness Medical Innovations

11-Jan-2008

BioCurex and Inverness Medical Innovations have announced a licensing agreement for BioCurex's RECAF material and technology. RECAF (the receptor for alpha-fetoprotein) is a wide-spectrum marker present in malignant cancer cells and absent in most normal cells, allowing it to play a major role in the development of new diagnostic tests for prostate, breast, colorectal, lung and other cancers. More than three years of testing by BioCurex has confirmed RECAF's high degree of clinical sensitivity and specificity in detecting various types of cancer, even when the disease is at its earliest stage.

Under terms of the license agreement, Inverness Medical Innovations will obtain semi-exclusive worldwide rights to commercialize products using this technology. BioCurex will be paid up-front fees, product and development milestones plus royalties on product sales.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures